It was recently reported here that nesvacumab (REGN910) was being tested in combination with Eylea (Regeneron) as a potential treatment for wet AMD. Regeneron, however, reported on November 27 that the results “did not provide sufficient differentiation to warrant Phase 3 development.” The Phase 2 trials have, therefore, been discontinued, and research data will be […]
Since 2005, anti-VEGF drug injections have proved effective for treatment of neovascularization* secondary to age-related macular degeneration (AMD) and diabetic macular edema (DME). Several newer anti-VEGF therapies are also under study, including PAN-90806, OPT-302, ICON-1, RGX-314, and RTH258. All of these are described and sourced on this site. Recently, scientists have researched a possible counterpart […]
A recent observational study at the University of Wisconsin-Madison has found that the risk of developing age-related macular degeneration (AMD) has been dramatically lessening over three generations. After looking at follow-up data on 4,819 participants and their offspring in the Beaver Dam studies (1987-2013), Karen J. Cruickshanks, Ph.D. et al found that the incidence of […]
Results from two new clinical trials have added support for the use of human embryonic stem cells as treatment for the dry form of macular degeneration. Stem cells injected into the eye appear to have replaced the missing cells damaged by the disease, with no serious side effects. One study suggests it may have even improved patients’ […]
We announced here in July that Microsoft had released Seeing AI, a free app that harnesses the power of Artificial Intelligence (AI) to audibly read text, identify objects, and describe people. The app was originally available only in the United States, but it is now also in the British, Irish and Australian App stores. It is still available only for iOS devices […]
(Updated 9/26/19) Swiss drugmaker Novartis has announced that their new anti-VEGF drug, brolucizumab (RTH258), is meeting expectations as a potentially more effective and longer lasting treatment for wet macular degeneration than at least one of the current options. Positive results from two Phase III studies of brolucizumab versus aflibercept (Eylea) were presented at the American […]